La Jolla Pharmaceutical Co - ESG Rating & Company Profile powered by AI
Other companies in the rating industry group for La Jolla Pharmaceutical Co are displayedin the table. Comprehensive Sustainability assessment of La Jolla Pharmaceutical Co can be reached by logging in. The page contains a free Environmental, Social and Governance analysis covering La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | La Jolla Pharmaceutical Co | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does La Jolla Pharmaceutical Co have an accelerator or VC vehicle to help deliver innovation?
Does La Jolla Pharmaceutical Co disclose current and historical energy intensity?
Does La Jolla Pharmaceutical Co report the average age of the workforce?
Does La Jolla Pharmaceutical Co reference operational or capital allocation in relation to climate change?
Does La Jolla Pharmaceutical Co disclose its ethnicity pay gap?
Does La Jolla Pharmaceutical Co disclose cybersecurity risks?
Does La Jolla Pharmaceutical Co offer flexible work?
Does La Jolla Pharmaceutical Co have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does La Jolla Pharmaceutical Co disclose the number of employees in R&D functions?
Does La Jolla Pharmaceutical Co conduct supply chain audits?
Does La Jolla Pharmaceutical Co disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does La Jolla Pharmaceutical Co conduct 360 degree staff reviews?
Does La Jolla Pharmaceutical Co disclose the individual responsible for D&I?
Does La Jolla Pharmaceutical Co disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does La Jolla Pharmaceutical Co disclose current and / or historical scope 2 emissions?
Does La Jolla Pharmaceutical Co disclose water use targets?
Does La Jolla Pharmaceutical Co have careers partnerships with academic institutions?
Did La Jolla Pharmaceutical Co have a product recall in the last two years?
Does La Jolla Pharmaceutical Co disclose incidents of discrimination?
Does La Jolla Pharmaceutical Co allow for Work Councils/Collective Agreements to be formed?
Has La Jolla Pharmaceutical Co issued a profit warning in the past 24 months?
Does La Jolla Pharmaceutical Co disclose parental leave metrics?
Does La Jolla Pharmaceutical Co disclose climate scenario or pathway analysis?
Does La Jolla Pharmaceutical Co disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does La Jolla Pharmaceutical Co disclose the pay ratio of women to men?
Does La Jolla Pharmaceutical Co support suppliers with sustainability related research and development?
Does La Jolla Pharmaceutical Co disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does La Jolla Pharmaceutical Co reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is La Jolla Pharmaceutical Co involved in embryonic stem cell research?
Does La Jolla Pharmaceutical Co disclose GHG and Air Emissions intensity?
Does La Jolla Pharmaceutical Co disclose its waste policy?
Does La Jolla Pharmaceutical Co report according to TCFD requirements?
Does La Jolla Pharmaceutical Co disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does La Jolla Pharmaceutical Co disclose energy use targets?
Does La Jolla Pharmaceutical Co disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does La Jolla Pharmaceutical Co have a policy relating to cyber security?
Have a different question?
Potential Risks for La Jolla Pharmaceutical Co
These potential risks are based on the size, segment and geographies of the company.
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.